The positivity rates for the apoA2-i Index and CA19-9 in PC patients were both 0%, respectively, in those with intraductal tumor spread less than 5 mm and 25.0% and 12.5%, respectively, in PC cases with intraductal tumor spread ranging from 5 to 10 mm. This evidence concerns the gene APOA2 and pachyonychia congenita.